Clinuvel Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO Clinuvel Pharmaceuticals is Philippe Wolgen, benoemd in Nov2005, heeft een ambtstermijn van 19.08 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 3.74M, bestaande uit 47.2% salaris en 52.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 6.86% van de aandelen van het bedrijf, ter waarde A$ 45.08M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 5 jaar.
Belangrijke informatie
Philippe Wolgen
Algemeen directeur
AU$3.7m
Totale compensatie
| Percentage CEO-salaris | 47.2% |
| Dienstverband CEO | 19yrs |
| Eigendom CEO | 6.9% |
| Management gemiddelde ambtstermijn | less than a year |
| Gemiddelde ambtstermijn bestuur | 5yrs |
Recente managementupdates
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | AU$4m | AU$2m | AU$36m |
| Mar 31 2024 | n/a | n/a | AU$33m |
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
Compensatie versus markt: De totale vergoeding ($USD 2.44M ) Philippe } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 910.58K ).
Compensatie versus inkomsten: De vergoeding van Philippe is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Philippe Wolgen (61 yo)
19yrs
Tenure
AU$3,742,412
Compensatie
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, MD & Director | 19yrs | AU$3.74m | 6.86% A$ 45.9m | |
| Chief Scientific Officer | 12.2yrs | AU$782.61k | 0.38% A$ 2.5m | |
| Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Operations Officer | no data | geen gegevens | geen gegevens | |
| Head of Australian Operations & Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs | less than a year | geen gegevens | geen gegevens | |
| Head of Quality Assurance & Drug Safety | less than a year | geen gegevens | geen gegevens | |
| Company Secretary | less than a year | geen gegevens | geen gegevens |
0.9yrs
Gemiddelde duur
Ervaren management: Het managementteam van CUV wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, MD & Director | 19.1yrs | AU$3.74m | 6.86% A$ 45.9m | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
| Non-Executive Director | 5.2yrs | AU$80.00k | 0.00084% A$ 5.6k | |
| Non-Executive Chairman | 5yrs | AU$91.67k | 0.0063% A$ 42.2k | |
| Non-Executive Director | 6.8yrs | AU$75.00k | 0.028% A$ 185.4k | |
| Non-Executive Director | less than a year | geen gegevens | geen gegevens |
5.0yrs
Gemiddelde duur
Ervaren bestuur: De raad van bestuur van CUV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).